August 14, 2025 | 12:00 - 12:45 PM ET
Medicare Part D is undergoing its most significant transformation in decades largely driven by the Inflation Reduction Act (IRA). What does this mean for pharmaceutical manufacturers? Join us for an engaging discussion with Max Hunt, Partner at Trinity Life Sciences, and special guest Dan Simenc, clinical and actuarial expert at Milliman, as they provide perspectives on recent developments and future expectations for Medicare Part D and Medicare Advantage.
The purpose of this study was to systematically assess rates of treatment-emergent hypophosphatemia among IDI formulations used in IDA. Authors Lim-Watson M, Libre M, Karkare S, Alkhateeb Z, Hadker N, Bajic-Lucas A, Dahl N, Strauss W, Glaspy J Journal ISPOR Meeting, May 2019 View publication…
Obesity is a disease that is caused and influenced by genes and the environment. Whether different etiologies or presentations of obesity result in homogeneous disease burden and/or cost is not well characterized. The objective is to determine whether there are distinct segments within the pool of patients who are obese that are differentiated by clinical characteristics, and quantify their healthcare resource utilization (direct healthcare costs [HCC]), using U.S. claims data. Authors Marissa Suh, Monica Fay, Amy McCagg, Ida Moeller, Scott…
Pharma and biotech companies are innovation drivers at the frontlines of research and development. To fund and support this promising science, there is a great need for partnerships and mergers and acquisitions (M&A) to drive the growth/pipeline of the industry. For these collaborative relationships to occur, understanding the value of a company’s underlying assets is of the utmost importance. Since Trinity’s founding, multiple pharma and biotech clients have relied on its expertise in forecast and valuing assets. These engagements have…
By signing up, you are agreeing to our Privacy Policy.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
